Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase Ib Study of DSP107 for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

X
Trial Profile

An Open-label Phase Ib Study of DSP107 for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DSP 107 (Primary) ; Azacitidine; Azacitidine; Venetoclax
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Lymphoproliferative disorders; Myelodysplastic syndromes; T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors KAHR Medical
  • Most Recent Events

    • 09 Mar 2023 Planned End Date changed from 1 Apr 2023 to 1 Dec 2024.
    • 09 Mar 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Aug 2024.
    • 17 Feb 2022 According to a KAHR Medical media release, first patient has been dosed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top